Re­gen­eron culls two drugs from pipeline amid dou­ble-dig­it rev­enue drop af­ter Covid mAb cock­tail pull

It’s not al­ways a good sign when a com­pa­ny re­ports a sub­stan­tial mar­ket drop, but part of the drop is just mov­ing for­ward.

Re­gen­eron, head­ed by bil­lion­aires CEO Leonard Schleifer and CSO George Yan­copou­los, re­port­ed Q3 earn­ings Thurs­day morn­ing — qui­et­ly not­ing a 15% drop in rev­enue com­pared to Q3 last year, pulling in $2.94 bil­lion.

Schleifer sought to blunt the drop in the com­pa­ny’s over­all num­bers, telling in­vestors and an­a­lysts on the earn­ings call that “to­tal rev­enues for the quar­ter in­creased by 11% com­pared to last year, when ex­clud­ing con­tri­bu­tions from our COVID an­ti­body cock­tail.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER